AcuityMD, a leading AI platform for the medical technology sector, has successfully secured $80 million in a Series C funding round. The investment, led by existing investor StepStone Group, elevates the company's valuation to $955 million, positioning it near unicorn status. This new capital infusion will fuel the launch of its new AcuityAI capabilities and advance the company's mission to accelerate the adoption of innovative medical devices.
Strategic Investment for AI Advancement
The funding round saw participation from existing investors including Benchmark, Redpoint Ventures, ICONIQ, and Atreides Management, signaling strong confidence in the company's direction. Hunter Somerville, a Partner at StepStone Group, highlighted the company's meaningful data advantage and its potential to benefit the broader MedTech organization. This commitment reinforces AcuityMD's rapid scaling and thoughtful investment in its platform and personnel, bringing its total funding to over $160 million.
Addressing MedTech Commercial Challenges
Medical technology companies operate in a highly dynamic environment, facing pressures from portfolio changes, hospital consolidation, and fluctuating regulations. These shifts can quickly alter the competitive landscape, making it difficult for commercial teams to keep pace with market opportunities. AcuityMD was developed to address this core challenge by centralizing critical commercial insights for its clients, which include 16 of the top 20 MedTech companies.
The Power of a Proprietary Ontology
The platform's foundation is a proprietary MedTech ontology that aggregates scattered information from claims databases, FDA filings, and other market signals. This continuously enriched knowledge graph maps key entities like physicians, facilities, procedures, and their complex interrelationships. By aligning this ontology with a customer's internal data, AcuityMD provides a unified, constantly updated view of the healthcare market for smarter commercial execution.
Introducing AcuityAI for Enhanced Sales
Building on this robust data foundation, the company has launched AcuityAI, which is now available in open beta. This new tool connects the ontology with a company's specific business context to deliver highly relevant answers that generic AI platforms cannot replicate. The system empowers sales representatives to spend less time on research and more time engaging with the right physicians, armed with better context.
The practical benefits of this technology are already being realized by early adopters. Mark Edwards, senior director of sales operations at Kuros Biosciences, noted that AcuityAI provides his team with sharper answers much faster than before. He shared an example of a sales leader generating a full business plan for a new national contract in minutes, highlighting the platform's efficiency.
Future Growth and Platform Expansion
With the new capital, AcuityMD will focus on three strategic priorities to drive its next phase of growth. The company plans to accelerate the development of agentic AI capabilities for sales, leadership, and marketing teams. It will also work to deepen the complex MedTech ontology that underpins its data model and insights, enhancing its core competitive advantage.
A key part of the company's long-term vision involves expanding the platform's application beyond commercial functions. This strategic move aims to support the entire product lifecycle within MedTech organizations. The goal is to further embed AcuityMD's technology to accelerate the adoption of medical innovations from development through to market launch and beyond.
In summary, the $80 million funding round marks a pivotal moment for AcuityMD, enabling significant advancements in its AI-driven platform. CEO and co-founder Mike Monovoukas emphasized that contextual AI, deeply embedded in workflows, is essential for transforming the MedTech industry. This investment solidifies AcuityMD's position as a key partner for MedTech companies aiming to bring cutting-edge technologies to patients faster.